Mannan-conjugated birch pollen allergoids continuously reduce the combined symptom and medication score with increasing treatment duration in birch pollen allergic patients

被引：0

作者：

Neuhof, C. ^{[1
]}

Raskopf, E. ^{[1
]}

England, L. ^{[1
]}

Singh, J. ^{[1
]}

Sahin, H. ^{[1
]}

Radtke, L. ^{[1
]}

Zeyen, C. ^{[2
]}

Hueffmeier, F. ^{[2
]}

Cuevas, M. ^{[3
]}

Casanovas, M. ^{[4
]}

Subiza, J. L. ^{[4
]}

Allekotte, S. ^{[1
]}

Moesges, R. ^{[1
]}

机构：

[1] ClinCompetence Cologne GmbH, Cologne, Germany

[2] Univ Cologne, Med Fak, Cologne, Germany

[3] Tech Univ Dresden, Klinikum Carl Gustav Carus, Dresden, Germany

[4] Inmunotek SL, Madrid, Spain

来源：

ALLERGOLOGIE | 2022年 / 45卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

P1.07

引用

页码：597 / 597

页数：1

共 29 条

[21] Relation between grass pollen count and Combined Symptom and Medication Score in grass allergic patients
Berger, U.
Higenbottam, T.
Lee, D.
Wessiepe, D.
Rueckinger, S.
Skinner, M. A.
ALLERGY, 2018, 73 : 484 - 484
[22] Induction of Allergen-Neutralizing IgG4 and IgA Blocking Antibodies Following Subcutaneous Immunotherapy with Mannan-Conjugated Birch Pollen Allergoid
Devine, Alistair
Raskopf, Esther
Parkin, Rebecca
Palmer, Elizabeth
Radtke, Lea
Casanovas, Miguel
Cuevas, Mandy
Moesges, Ralph
Shamji, Mohamed
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB72 - AB72
[23] Phase III trial with allergen specific sublingual immunotherapy in birch allergic patients: significant and clinical relevant reduction of the combined symptom and medication score
Pfaar, O.
Kuna, P.
Panzner, P.
Dzupinova, M.
Kiimek, L.
van Nimwegen, M.
Boot, D.
de Kam, P-J
Bachert, C.
ALLERGY, 2016, 71 : 44 - 45
[24] Efficacy of sublingual immunotherapy with grass pollen tablets on rescue medication score (RMS) and combined symptom/medication score (CS) in patients with rhinoconjunctivitis
Montagut, A.
de Beaumont, O.
Melac, M.
Le Gall, M.
ALLERGY, 2008, 63 : 228 - 228
[25] Full symptom control in patients with allergic rhinoconjunctivitis induced by birch pollen treated with sublingual allergen immunotherapy (AIT) in real-life medical practice
Hadler, M.
Karagiannis, E.
Shah-Hosseini, K.
Moesges, R.
ALLERGY, 2014, 69 : 509 - 509
[26] Correlation of symptom score and peak nasal inspiratory flow following a standardised titrated nasal provocation test with a birch pollen extract in a multi-centre clinical study in allergic rhinitis
Pfaar, O.
van Twuijver, E.
Boot, D.
Klimek, L.
Nienhuis, H.
Diamant, Z.
Kuna, P.
Panzner, P.
ALLERGY, 2013, 68 : 183 - 184
[27] Significant benefits of combined symptom and medication scores for ultra short course subcutaneous immunotherapy compared with placebo in patients with grass pollen allergic rhinoconjunctivitis
Frew, A.
DuBuske, L.
Amersdorffer, J.
Holdich, T.
ALLERGY, 2009, 64 : 227 - 228
[28] Significant Reduction In Combined Symptom And Medication Score Compared With Placebo Following MPL-Adjuvanted uSCIT In Patients With Seasonal Grass Pollen Allergy
DuBuske, L. M.
Castells, M.
Holdich, T.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S216 - S216
[29] AIT is associated with reduced risk of asthma medication initiation and evolution up to 6 years after stopping AIT in patients with birch family pollen-induced allergic rhinitis and/or asthma
Zielen, S.
Wahn, U.
Bachert, C.
Richter, H.
Heinrich, J.
ALLERGY, 2018, 73 : 340 - 340

← 1 2 3 →